未名医药
(002581)
| 流通市值：35.51亿 | | | 总市值：58.45亿 |
| 流通股本：4.01亿 | | | 总股本：6.60亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 445,010,515.55 | 506,403,730 | 388,846,865.13 | 394,388,874.79 |
| 结算备付金 | - | 0 | - | - |
| 拆出资金 | - | 0 | - | - |
| 衍生金融资产 | - | 0 | - | - |
| 应收票据及应收账款 | 67,968,200.52 | 87,212,629.11 | 124,255,461.9 | 150,954,736.47 |
| 其中：应收票据 | 10,629,468.74 | 14,156,358.57 | 7,951,736.21 | 5,694,425.03 |
| 应收账款 | 57,338,731.78 | 73,056,270.54 | 116,303,725.69 | 145,260,311.44 |
| 应收款项融资 | 7,970,524.25 | 6,104,405.02 | 20,156,983.63 | 17,725,549.41 |
| 预付款项 | 10,954,243.1 | 10,206,566.9 | 9,778,730.09 | 2,969,016.3 |
| 应收保费 | - | 0 | - | - |
| 应收分保账款 | - | 0 | - | - |
| 应收分保合同准备金 | - | 0 | - | - |
| 其他应收款合计 | 101,177,639.42 | 51,217,188.79 | 53,479,635.4 | 52,760,451.63 |
| 买入返售金融资产 | - | 0 | - | - |
| 存货 | 87,706,029.64 | 79,638,901.06 | 81,077,832.89 | 78,916,263.59 |
| 合同资产 | - | 0 | - | - |
| 一年内到期的非流动资产 | - | 0 | - | - |
| 其他流动资产 | 9,088,857.27 | 6,223,917.31 | 3,358,580.9 | 3,623,609.04 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 729,876,009.75 | 747,007,338.19 | 721,882,905.32 | 742,267,316.61 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | 0 | - | - |
| 债权投资 | - | 0 | - | - |
| 其他债权投资 | - | 0 | - | - |
| 长期应收款 | - | 0 | - | - |
| 长期股权投资 | 1,048,822,473.33 | 1,055,730,183.04 | 1,144,374,143.94 | 1,088,381,252.18 |
| 其他权益工具投资 | - | 0 | - | - |
| 其他非流动金融资产 | - | 0 | - | - |
| 投资性房地产 | - | 0 | - | - |
| 固定资产 | 230,230,880.69 | 236,370,085.88 | 285,780,080.74 | 292,679,355.85 |
| 在建工程 | 38,342,087.87 | 38,109,424.71 | 21,055,309.43 | 21,019,342 |
| 生产性生物资产 | - | 0 | - | - |
| 油气资产 | - | 0 | - | - |
| 使用权资产 | 4,138,714.77 | 262,200.06 | 303,600.07 | 394,365.09 |
| 无形资产 | 91,646,199.5 | 93,470,477.49 | 102,444,893.3 | 104,400,391.39 |
| 开发支出 | - | 0 | - | - |
| 商誉 | - | 0 | - | - |
| 长期待摊费用 | 284,497.4 | 323,090.49 | 361,683.59 | 711,527.36 |
| 递延所得税资产 | 12,845,448.72 | 11,205,833.94 | 5,706,975.42 | 5,880,949.07 |
| 其他非流动资产 | 11,657,484.64 | 13,439,954.4 | 13,978,249.31 | 13,679,243.19 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,437,967,786.92 | 1,448,911,250.01 | 1,574,004,935.8 | 1,527,146,426.13 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,167,843,796.67 | 2,195,918,588.2 | 2,295,887,841.12 | 2,269,413,742.74 |
| 流动负债: | | | | |
| 短期借款 | 2,298,036.84 | 2,766,405.84 | 0 | 10,000,000 |
| 向中央银行借款 | - | 0 | - | - |
| 吸收存款及同业存放 | - | 0 | - | - |
| 拆入资金 | - | 0 | - | - |
| 交易性金融负债 | - | 0 | - | - |
| 衍生金融负债 | - | 0 | - | - |
| 应付票据及应付账款 | 25,890,383.88 | 35,349,368.69 | 35,660,435.18 | 35,095,422.3 |
| 其中：应付票据 | - | 0 | - | - |
| 应付账款 | 25,890,383.88 | 35,349,368.69 | 35,660,435.18 | 35,095,422.3 |
| 预收款项 | - | 0 | - | - |
| 合同负债 | 27,254,494.74 | 10,459,681.65 | 6,095,571.95 | 5,713,456.77 |
| 卖出回购金融资产款 | - | 0 | - | - |
| 应付手续费及佣金 | - | 0 | - | - |
| 应付职工薪酬 | 4,617,681.8 | 11,406,123.96 | 7,951,267.01 | 4,847,344.11 |
| 应交税费 | 1,781,188.5 | 2,361,906.06 | 4,414,231.66 | 4,883,763.02 |
| 其他应付款合计 | 29,197,062.35 | 18,032,037.89 | 10,432,733.93 | 25,703,280.08 |
| 应付分保账款 | - | 0 | - | - |
| 保险合同准备金 | - | 0 | - | - |
| 代理买卖证券款 | - | 0 | - | - |
| 代理承销证券款 | - | 0 | - | - |
| 一年内到期的非流动负债 | 0 | 168,935.77 | - | - |
| 其他流动负债 | 0 | 2,060,808.94 | 0 | - |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 91,038,848.11 | 82,605,268.8 | 64,554,239.73 | 86,243,266.28 |
| 非流动负债: | | | | |
| 长期借款 | - | 0 | - | - |
| 应付债券 | - | 0 | - | - |
| 优先股 | - | 0 | - | - |
| 永续债 | - | 0 | - | - |
| 租赁负债 | 4,009,167.07 | - | 209,428.52 | 320,436.73 |
| 长期应付款 | - | 0 | - | - |
| 长期应付职工薪酬 | - | 0 | - | - |
| 预计负债 | 79,732,340 | 76,122,074.61 | 13,197,336.43 | 16,788,572.01 |
| 递延收益 | 5,493,692.1 | 5,493,692.1 | 5,168,505.81 | 5,276,901.24 |
| 递延所得税负债 | 10,418,083.84 | 9,390,967.58 | 7,759,231.54 | 7,426,647.78 |
| 其他非流动负债 | - | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 99,653,283.01 | 91,006,734.29 | 26,334,502.3 | 29,812,557.76 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 190,692,131.12 | 173,612,003.09 | 90,888,742.03 | 116,055,824.04 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 229,145,299 | 229,145,299 | 229,145,299 | 229,145,299 |
| 其他权益工具 | - | 0 | - | - |
| 优先股 | - | 0 | - | - |
| 永续债 | - | 0 | - | - |
| 资本公积 | 871,010,838.24 | 866,412,583.85 | 881,203,262.29 | 878,378,556.33 |
| 减:库存股 | - | 0 | - | - |
| 其他综合收益 | - | 0 | - | - |
| 专项储备 | - | 0 | - | - |
| 盈余公积 | 152,522,396.39 | 152,522,396.39 | 152,522,396.39 | 152,522,396.39 |
| 一般风险准备 | - | 0 | - | - |
| 未分配利润 | 638,703,716.83 | 675,554,114 | 827,493,954.31 | 783,252,768.94 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,891,382,250.46 | 1,923,634,393.24 | 2,090,364,911.99 | 2,043,299,020.66 |
| 少数股东权益 | 85,769,415.09 | 98,672,191.87 | 114,634,187.1 | 110,058,898.04 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,977,151,665.55 | 2,022,306,585.11 | 2,204,999,099.09 | 2,153,357,918.7 |
| 负债和股东权益合计 | 2,167,843,796.67 | 2,195,918,588.2 | 2,295,887,841.12 | 2,269,413,742.74 |
| 公告日期 | 2025-04-29 | 2025-04-24 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 保留意见 | | |